Loading...
XWARBMX
Market cap11mUSD
Dec 23, Last price  
10.75PLN
1D
-4.87%
1Q
-24.56%
Jan 2017
122.11%
IPO
36.08%
Name

BioMaxima SA

Chart & Performance

D1W1MN
XWAR:BMX chart
P/E
76.92
P/S
0.96
EPS
0.14
Div Yield, %
4.65%
Shrs. gr., 5y
2.97%
Rev. gr., 5y
8.71%
Revenues
47m
-67.48%
6,669,4287,163,84610,491,70518,818,62020,965,51020,440,95521,965,26026,984,19831,574,52630,817,69230,487,87061,609,50879,088,000143,867,00046,786,000
Net income
586k
-97.97%
610,366539,042998,9531,375,0641,320,371454,8331,454,7471,227,716805,683013,9987,949,00010,243,00028,885,000586,000
CFO
2m
-95.70%
418,323102,8851,832,45101,249,426561,0162,286,8831,439,1421,839,4002,120,2564,927,7823,972,697-132,00037,065,0001,592,000
Dividend
Jun 16, 20230.5 PLN/sh

Profile

BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.
URL
https://biomaxima.com/
IPO date
Jun 08, 2010
Employees
122
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
46,786
-67.48%
143,867
81.91%
79,088
28.37%
Cost of revenue
45,818
89,637
54,811
Unusual Expense (Income)
NOPBT
968
54,230
24,277
NOPBT Margin
2.07%
37.69%
30.70%
Operating Taxes
(399)
6,984
2,532
Tax Rate
12.88%
10.43%
NOPAT
1,367
47,246
21,745
Net income
586
-97.97%
28,885
182.00%
10,243
28.86%
Dividends
(2,097)
(1,948)
(1,097)
Dividend yield
2.96%
1.70%
0.93%
Proceeds from repurchase of equity
45
(4,991)
BB yield
-0.06%
4.36%
Debt
Debt current
3,797
1,718
8,651
Long-term debt
9,767
4,772
9,729
Deferred revenue
6,871
6,019
6,173
Other long-term liabilities
102
94
62
Net debt
12,061
(6,430)
18,058
Cash flow
Cash from operating activities
1,592
37,065
(132)
CAPEX
(18,079)
(9,879)
(4,482)
Cash from investing activities
(17,248)
(7,831)
(3,368)
Cash from financing activities
4,252
(19,323)
2,110
FCF
(12,094)
44,623
24,989
Balance
Cash
1,503
12,920
321
Long term investments
1,000
Excess cash
5,727
Stockholders' equity
37,038
46,769
19,352
Invested Capital
66,808
58,670
51,991
ROIC
2.18%
85.39%
46.31%
ROCE
1.44%
83.22%
46.22%
EV
Common stock shares outstanding
4,318
4,459
4,482
Price
16.42
-36.11%
25.70
-2.28%
26.30
-4.71%
Market cap
70,900
-38.13%
114,591
-2.79%
117,877
-0.47%
EV
82,961
108,161
135,935
EBITDA
3,456
56,250
25,931
EV/EBITDA
24.00
1.92
5.24
Interest
609
475
200
Interest/NOPBT
62.91%
0.88%
0.82%